Literature DB >> 19740696

Identifying druggable disease-modifying gene products.

Scott J Dixon1, Brent R Stockwell.   

Abstract

Many disease genes encode proteins that are difficult to target directly using small molecule drugs. Improvements in libraries based on synthetic compounds, natural products, and other types of molecules may ultimately allow some challenging proteins to be successfully targeted; however, these developments alone are unlikely to be sufficient. A complementary strategy exploits the functional interconnectivity of intracellular networks to find druggable targets lying upstream, downstream, or in parallel to a disease-causing gene, where modulation can influence the disease process indirectly. These targets can be selected using prior knowledge of disease-associated pathways or identified using phenotypic chemical and genetic screens in model organisms and cells. These approaches should facilitate the identification of effective drug targets for many genetic disorders.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19740696      PMCID: PMC2787993          DOI: 10.1016/j.cbpa.2009.08.003

Source DB:  PubMed          Journal:  Curr Opin Chem Biol        ISSN: 1367-5931            Impact factor:   8.822


  62 in total

1.  Exploring the mode-of-action of bioactive compounds by chemical-genetic profiling in yeast.

Authors:  Ainslie B Parsons; Andres Lopez; Inmar E Givoni; David E Williams; Christopher A Gray; Justin Porter; Gordon Chua; Richelle Sopko; Renee L Brost; Cheuk-Hei Ho; Jiyi Wang; Troy Ketela; Charles Brenner; Julie A Brill; G Esteban Fernandez; Todd C Lorenz; Gregory S Payne; Satoru Ishihara; Yoshikazu Ohya; Brenda Andrews; Timothy R Hughes; Brendan J Frey; Todd R Graham; Raymond J Andersen; Charles Boone
Journal:  Cell       Date:  2006-08-11       Impact factor: 41.582

2.  A stapled BID BH3 helix directly binds and activates BAX.

Authors:  Loren D Walensky; Kenneth Pitter; Joel Morash; Kyoung Joon Oh; Scott Barbuto; Jill Fisher; Eric Smith; Gregory L Verdine; Stanley J Korsmeyer
Journal:  Mol Cell       Date:  2006-10-20       Impact factor: 17.970

3.  Druggability of human disease genes.

Authors:  Meena Kishore Sakharkar; Kishore Ramaji Sakharkar; Shazib Pervaiz
Journal:  Int J Biochem Cell Biol       Date:  2007-03-07       Impact factor: 5.085

4.  Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseases.

Authors:  Ruth A Bodner; Tiago Fleming Outeiro; Stephen Altmann; Michele M Maxwell; Stephanie H Cho; Bradley T Hyman; Pamela J McLean; Anne B Young; David E Housman; Aleksey G Kazantsev
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-06       Impact factor: 11.205

5.  Reactivation of the p53 tumor suppressor pathway by a stapled p53 peptide.

Authors:  Federico Bernal; Andrew F Tyler; Stanley J Korsmeyer; Loren D Walensky; Gregory L Verdine
Journal:  J Am Chem Soc       Date:  2007-02-07       Impact factor: 15.419

Review 6.  Discovery and development of anticancer aptamers.

Authors:  Christopher R Ireson; Lloyd R Kelland
Journal:  Mol Cancer Ther       Date:  2006-12       Impact factor: 6.261

7.  BRAF mutation predicts sensitivity to MEK inhibition.

Authors:  David B Solit; Levi A Garraway; Christine A Pratilas; Ayana Sawai; Gad Getz; Andrea Basso; Qing Ye; Jose M Lobo; Yuhong She; Iman Osman; Todd R Golub; Judith Sebolt-Leopold; William R Sellers; Neal Rosen
Journal:  Nature       Date:  2005-11-06       Impact factor: 49.962

8.  RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels.

Authors:  Nicholas Yagoda; Moritz von Rechenberg; Elma Zaganjor; Andras J Bauer; Wan Seok Yang; Daniel J Fridman; Adam J Wolpaw; Inese Smukste; John M Peltier; J Jay Boniface; Richard Smith; Stephen L Lessnick; Sudhir Sahasrabudhe; Brent R Stockwell
Journal:  Nature       Date:  2007-06-14       Impact factor: 49.962

9.  Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease.

Authors:  Tiago Fleming Outeiro; Eirene Kontopoulos; Stephen M Altmann; Irina Kufareva; Katherine E Strathearn; Allison M Amore; Catherine B Volk; Michele M Maxwell; Jean-Christophe Rochet; Pamela J McLean; Anne B Young; Ruben Abagyan; Mel B Feany; Bradley T Hyman; Aleksey G Kazantsev
Journal:  Science       Date:  2007-06-21       Impact factor: 47.728

10.  Selective inhibitors of death in mutant huntingtin cells.

Authors:  Hemant Varma; Cindy Voisine; C Todd DeMarco; Elena Cattaneo; Donald C Lo; Anne C Hart; Brent R Stockwell
Journal:  Nat Chem Biol       Date:  2006-12-31       Impact factor: 15.040

View more
  23 in total

1.  Disease allele-dependent small-molecule sensitivities in blood cells from monogenic diabetes.

Authors:  Stanley Y Shaw; David M Blodgett; Maggie S Ma; Elizabeth C Westly; Paul A Clemons; Aravind Subramanian; Stuart L Schreiber
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-23       Impact factor: 11.205

Review 2.  Cellular models for disease exploring and drug screening.

Authors:  Zhi-Kun Li; Qi Zhou
Journal:  Protein Cell       Date:  2010-05-08       Impact factor: 14.870

3.  Potent and selective inhibition of a single alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor subunit by an RNA aptamer.

Authors:  Jae-Seon Park; Congzhou Wang; Yan Han; Zhen Huang; Li Niu
Journal:  J Biol Chem       Date:  2011-03-14       Impact factor: 5.157

4.  Photocleavable dimerizer for the rapid reversal of molecular trap antagonists.

Authors:  Shubbir Ahmed; Jun Xie; David Horne; John C Williams
Journal:  J Biol Chem       Date:  2014-01-13       Impact factor: 5.157

5.  Treating Cystic Fibrosis with mRNA and CRISPR.

Authors:  Alejandro Da Silva Sanchez; Kalina Paunovska; Ana Cristian; James E Dahlman
Journal:  Hum Gene Ther       Date:  2020-09-08       Impact factor: 5.695

Review 6.  Systems genetics for drug target discovery.

Authors:  Nadia M Penrod; Richard Cowper-Sal-lari; Jason H Moore
Journal:  Trends Pharmacol Sci       Date:  2011-08-19       Impact factor: 14.819

Review 7.  A survey of yeast genomic assays for drug and target discovery.

Authors:  Andrew M Smith; Ron Ammar; Corey Nislow; Guri Giaever
Journal:  Pharmacol Ther       Date:  2010-05-28       Impact factor: 12.310

Review 8.  Tapping the RNA world for therapeutics.

Authors:  Judy Lieberman
Journal:  Nat Struct Mol Biol       Date:  2018-04-16       Impact factor: 15.369

Review 9.  Activity-based protein profiling for mapping and pharmacologically interrogating proteome-wide ligandable hotspots.

Authors:  Allison M Roberts; Carl C Ward; Daniel K Nomura
Journal:  Curr Opin Biotechnol       Date:  2016-08-26       Impact factor: 9.740

10.  Chemoproteomics-Enabled Covalent Ligand Screening Reveals a Thioredoxin-Caspase 3 Interaction Disruptor That Impairs Breast Cancer Pathogenicity.

Authors:  Kimberly E Anderson; Milton To; James A Olzmann; Daniel K Nomura
Journal:  ACS Chem Biol       Date:  2017-09-13       Impact factor: 5.100

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.